Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Down - Should You Sell?

Key Points

• Gapped down: Santen shares opened at $10.45 versus a prior close of $11.025 and last traded at $10.52 on volume of 123,600 shares, down about 1.5%.
• Analyst stance: Zacks Research moved the stock to a Hold on April 13 and the MarketBeat consensus rating is currently Hold.
• Company and fundamentals: Santen is a global ophthalmology specialist with a market cap of $3.38 billion and a reported P/E of 0.10; its 50‑day and 200‑day simple moving averages are $11.04 and $10.66, respectively.

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $11.0250, but opened at $10.45. Santen Pharmaceutical shares last traded at $10.52, with a volume of 123,600 shares traded.

Analysts Set New Price Targets

Separately, Zacks Research raised Santen Pharmaceutical to a "hold" rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of "Hold".

Santen Pharmaceutical Stock Down 1.5%

The company has a 50 day simple moving average of $11.04 and a 200-day simple moving average of $10.66. The stock has a market cap of $3.38 billion and a price-to-earnings ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.